Tenax Therapeutics reports Q4/FY2025 loss; LEVEL study fully enrolled, topline Q3 2026

TENAX THERAPEUTICS, INC.

Achieved 230-patient randomization target in Phase 3 LEVEL study; topline data expected Q3 2026.
Cash and equivalents $97.6M as of Dec 31, 2025; expected to fund operations through 2027.
Full-year 2025 net loss $52.6M vs $17.6M in 2024; R&D spend $32.7M on trial expansion.
Initiated global Phase 3 LEVEL-2 trial and open-label extension for TNX-103 (levosimendan) in PH-HFpEF.
USPTO issued Notice of Allowance for subcutaneous levosimendan formulation in broad indications.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TENAX THERAPEUTICS, INC. reported year ended December 31, 2025 results: net income net loss of $52.6 million.

Period: year ended December 31, 2025
Net income: net loss of $52.6 million
Result: reported results

Exact text from the filing

Tenax Therapeutics reported a net loss of $52.6 million for the year ended December 31, 2025, compared to a net loss of $17.6 million for the year ended December 31, 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TENAX THERAPEUTICS, INC. reported fourth quarter ended December 31, 2025 results: net income net loss of $15.5 million.

Period: fourth quarter ended December 31, 2025
Net income: net loss of $15.5 million
Result: reported results

Exact text from the filing

Tenax Therapeutics reported a net loss of $15.5 million for the fourth quarter of 2025, compared to a net loss of $6.3 million for the fourth quarter of 2024.

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

TENAX THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001654954-26-002072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.